Shopping Cart
- Remove All
Your shopping cart is currently empty
IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated
Catalog No. TMPK-00082
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 20.5 kDa and the accession number is O95998-2.
IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated
Catalog No. TMPK-00082
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 20.5 kDa and the accession number is O95998-2.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 100 μg | $814 | 7-10 days | |
| 500 μg | $3,250 | 7-10 days | |
| 1 mg | $5,440 | 7-10 days |
Bulk & Custom
Add to Cart
Resource Download
Product Information
| Biological Activity | Biotinylated Human IL-18BP, His Tag captured on CM5 Chip via anti-his antibody can bind Human IL-18, No Tag with an affinity constant of 0.90 nM as determined in SPR assay. |
| Description | Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 20.5 kDa and the accession number is O95998-2. |
| Species | Human |
| Expression System | HEK293 Cells |
| Tag | C-His-Avi |
| Accession Number | O95998-2 |
| Synonyms | IL-18BPA,IL-18BP,Igifbp |
| Construction | Thr31-Gly194 |
| Protein Purity | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| Molecular Weight | 20.5 kDa (predicted). Due to glycosylation, the protein migrates to 52-65 kDa based on Tris-Bis PAGE result. |
| Endotoxin | < 1 EU/μg by the LAL method. |
| Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |
| Reconstitution | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
| Stability & Storage | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| Shipping | In general, Lyophilized powders are shipping with blue ice. |
| Research Background | Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. |
Dose Conversion
You can also refer to dose conversion for different animals. More
Calculator
Tech Support
Please read the User Guide of Recombinant Proteins for more specific information.
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.